Ko Wun Chang, Liao Chao-Chiun, Shih Chih-Hsien, Lei Chien-Bang, Chen Chi-Ming
Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan, ROC.
Planta Med. 2002 Nov;68(11):1004-9. doi: 10.1055/s-2002-35671.
We investigated the reason why butylidenephthalide (Bdph) can have an antianginal effect without changing blood pressure in conscious rats. Isolated dog coronary artery (CA), femoral vein (FV), femoral artery (FA), and mesenteric artery (MA) were used to evaluate the relaxant effects of Bdph. Bdph concentration-dependently relaxed isolated CA, FV, FA, and MA precontracted by KCl (60 mM) and phenylephrine (phe, 5 microM) with the exception that CA was precontracted by prostaglandin F 2 alpha (PGF 2 alpha, 2 microM) instead of phe. The potency order of Bdph to these blood vessels was FV > CA > FA > or = MA. Bdph also concentration-dependently and non-competitively inhibited cumulative KCl (5 - 120 mM)- and phe (0.1 - 100 microM)-induced contractions in normal, and inhibited cumulative Ca 2+-induced contractions in depolarized blood vessels. The potency order of Bdph to these blood vessels was FV congruent with CA > FA congruent with MA. Bdph (0.02 - 0.04 mM) concentration-dependently and leftward-shifted the log concentration-response curves in parallel and significantly increased the pD 2 value of forskolin, but not nitroprusside in FV. Bdph (0.1 mM) did both in CA. Bdph (0.225 - 0.45 mM) did the opposite to that of nitroprusside, but not forskolin, in FA. Bdph (0.45 - 0.9 mM) did neither in MA. Bdph (0.1 - 1 mM) significantly inhibited cAMP- but not cGMP-PDE activities in these four blood vessels, suggesting that Bdph more selectively inhibited the former in these tissues. The above results suggest that the higher potencies of Bdph on FV and CA than on FA and MA, may be interpreted as the reason why Bdph is useful in the treatment of angina pectoris without changing blood pressure, after Bdph administration in vivo, because the venoreturn may be reduced and the coronary flow may be increased without affecting the arterioles, such as MA, the main determinant of blood pressure. Abbreviations. Bdph:butylidenephthalide Phe:phenylephrine PGF 2alpha :prostaglandin F 2alpha CA:coronary artery FV:femoral vein FA:femoral artery MA:mesenteric artery cAMP:adenosine 3',5'-cyclic monophosphate cGMP:guanosine 3',5'-cyclic monophosphate PDE:phosphodiesterase
我们研究了丁烯基苯酞(Bdph)在清醒大鼠体内不改变血压却能产生抗心绞痛作用的原因。采用离体犬冠状动脉(CA)、股静脉(FV)、股动脉(FA)和肠系膜动脉(MA)来评估Bdph的舒张作用。Bdph能浓度依赖性地舒张由氯化钾(60 mM)和去氧肾上腺素(phe,5 microM)预收缩的离体CA、FV、FA和MA,其中CA是由前列腺素F2α(PGF2α,2 microM)而非phe预收缩。Bdph对这些血管的作用强度顺序为FV > CA > FA ≥ MA。Bdph还能浓度依赖性且非竞争性地抑制正常情况下氯化钾(5 - 120 mM)和phe(0.1 - 100 microM)诱导的累积收缩,并抑制去极化血管中钙离子诱导的累积收缩。Bdph对这些血管的作用强度顺序为FV ≈ CA > FA ≈ MA。Bdph(0.02 - 0.04 mM)能浓度依赖性地使FV中福斯高林的对数浓度 - 反应曲线平行左移,并显著增加其pD2值,但对硝普钠无此作用。Bdph(0.1 mM)对CA有上述两种作用。Bdph(0.225 - 0.45 mM)在FA中的作用与硝普钠相反,但对福斯高林无此作用。Bdph(0.45 - 0.9 mM)对MA均无上述作用。Bdph(0.1 - 1 mM)能显著抑制这四种血管中的环磷酸腺苷(cAMP) - 但不抑制环磷酸鸟苷(cGMP) - 磷酸二酯酶(PDE)活性,提示Bdph在这些组织中更具选择性地抑制前者。上述结果表明,Bdph对FV和CA的作用强度高于对FA和MA,这可能解释了Bdph在体内给药后可用于治疗心绞痛而不改变血压的原因,因为它可能在不影响作为血压主要决定因素的小动脉(如MA)的情况下减少静脉回心血量并增加冠状动脉血流量。缩写:Bdph:丁烯基苯酞;Phe:去氧肾上腺素;PGF2α:前列腺素F2α;CA:冠状动脉;FV:股静脉;FA:股动脉;MA:肠系膜动脉;cAMP:腺苷3',5'-环磷酸;cGMP:鸟苷3',5'-环磷酸;PDE:磷酸二酯酶